Celltrion Healthcare Co., Ltd.
091990
Clasificación en acciones
#2142
Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on... Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on the development, manufacturing, and distribution of biosimilar and biological therapeutic agents for patients around the globe. Its product lineup includes Remsima, a monoclonal antibody biosimilar used to treat various inflammatory and autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease in both adults and children, psoriasis, and psoriatic arthritis. Another significant offering, Truxima, targets conditions like lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, microscopic polyangiitis, and rheumatoid arthritis. Herzuma is prescribed for metastatic breast cancer, early-stage breast cancer, and metastatic gastric cancer. Additionally, Remsima SC provides a treatment option for rheumatoid arthritis. Founded in 1999, the enterprise was initially known as Nexol, Inc. before rebranding to Celltrion Healthcare Co., Ltd. in March 2009. The firm's corporate headquarters are situated in Incheon, South Korea.
Precio por acción
$57.75
Última sincronización: 2024-01-11
Capitalización bursátil
$9.42B
Cambio (1 día)
-0.25%
Cambio (1 año)
0.00%
País
KR
Comercio Celltrion Healthcare Co., Ltd. (091990)
Categoría
Healthcare
Ingresos de Celltrion Healthcare Co., Ltd. (091990)
Ingresos en Oct 2026 TTM: 0
Según los últimos informes financieros de Celltrion Healthcare Co., Ltd., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Celltrion Healthcare Co., Ltd. desde 2014 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2022 | $1.56B | 2.97% |
| 2021 | $1.52B | 1.24% |
| 2020 | $1.50B | 57.26% |
| 2019 | $953.35M | 48.78% |
| 2018 | $640.76M | -25.89% |
| 2017 | $864.65M | 37.82% |
| 2016 | $627.36M | 96.07% |
| 2015 | $319.97M | 110.23% |
| 2014 | $152.20M | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| $10.11B | - |
BE
|
